STOK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -46.35% compared to Stoke Therapeutics's net margin of 10.87%. Stoke Therapeutics's return on equity of -44.32% beat Biogen's return on equity of 10.33%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 158.95%. On the other hand Biogen has an analysts' consensus of $191.53 which suggests that it could grow by 61.1%. Given that Stoke Therapeutics has higher upside potential than Biogen, analysts believe Stoke Therapeutics is more attractive than Biogen.

Stoke Therapeutics has a beta of 1.089, which suggesting that the stock is 8.901% more volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are smaller than Biogen quarterly revenues of $2.5B. Stoke Therapeutics's net income of -$10.5M is lower than Biogen's net income of $266.7M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.58x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -46.35% compared to Stoke Therapeutics's net margin of -49.65%. Stoke Therapeutics's return on equity of -44.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 158.95%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.4%. Given that Stoke Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Stoke Therapeutics is more attractive than NovaBay Pharmaceuticals.

Stoke Therapeutics has a beta of 1.089, which suggesting that the stock is 8.901% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Stoke Therapeutics's net income of -$10.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.58x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -46.35% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of -44.32% beat Palatin Technologies's return on equity of --.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 158.95%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3233.33%. Given that Palatin Technologies has higher upside potential than Stoke Therapeutics, analysts believe Palatin Technologies is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 1.089, which suggesting that the stock is 8.901% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are larger than Palatin Technologies quarterly revenues of --. Stoke Therapeutics's net income of -$10.5M is higher than Palatin Technologies's net income of --. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.58x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -46.35% compared to Stoke Therapeutics's net margin of -75.75%. Stoke Therapeutics's return on equity of -44.32% beat Zymeworks's return on equity of -30.45%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 158.95%. On the other hand Zymeworks has an analysts' consensus of $21.35 which suggests that it could grow by 75.58%. Given that Stoke Therapeutics has higher upside potential than Zymeworks, analysts believe Stoke Therapeutics is more attractive than Zymeworks.

Stoke Therapeutics has a beta of 1.089, which suggesting that the stock is 8.901% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.59%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are smaller than Zymeworks quarterly revenues of $31M. Stoke Therapeutics's net income of -$10.5M is higher than Zymeworks's net income of -$23.5M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.58x versus 12.09x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.